Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 5, Pages 946
Publisher
MDPI AG
Online
2021-02-25
DOI
10.3390/cancers13050946
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical significance of homologous recombination deficiency score testing in endometrial Cancer
- (2021) Jean H. Siedel et al. GYNECOLOGIC ONCOLOGY
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer
- (2020) Fangfang Bi et al. Cancer Cell International
- Mismatch Repair Pathway, Genome Stability and Cancer
- (2020) Nives Pećina-Šlaus et al. Frontiers in Molecular Biosciences
- ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks
- (2019) Gabriel Balmus et al. Nature Communications
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Comparison between whole exome sequencing (WES) and single nucleotide polymorphism (SNP)-based tumor mutation burden analysis.
- (2019) Kirsten Timms et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Harnessing DNA Double-Strand Break Repair for Cancer Treatment
- (2019) Anika Trenner et al. Frontiers in Oncology
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy
- (2018) Euan A. Stronach et al. MOLECULAR CANCER RESEARCH
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.
- (2018) Melinda L. Telli et al. JOURNAL OF CLINICAL ONCOLOGY
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
- (2016) M. Moschetta et al. ANNALS OF ONCOLOGY
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Homologous recombination deficiency and ovarian cancer
- (2016) Jonathan A. Ledermann et al. EUROPEAN JOURNAL OF CANCER
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Inherited Mutations in Women With Ovarian Carcinoma
- (2016) Barbara M. Norquist et al. JAMA Oncology
- Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk
- (2015) Thaddeus Judkins et al. BMC CANCER
- Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation
- (2015) A. Bakr et al. NUCLEIC ACIDS RESEARCH
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- Hereditary ovarian cancer
- (2011) Kara C. Long et al. CURRENT OPINION IN ONCOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
- (2010) Bryan T.J. Hennessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology
- (2008) T. Pal et al. CLINICAL CANCER RESEARCH
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
- (2008) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search